burosumab

Ligand id: 9292

Name: burosumab

Classification
Compound class Antibody
Approved drug? Yes (EMA & FDA (2018))
International Nonproprietary Names
INN number INN
10301 burosumab
Synonyms
burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023
Comments
Burosumab (KRN23) is a fully human anti-FGF-23 monoclonal in clinical development. Such an anti-FGF-23 agent is considered suitable for prevention or treatment of diseases which are caused by hyperactivity of FGF-23 or for diseases whose pathology might be improved by controlling FGF-23 activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent US7883705, with the claimed antibody being abbreviated to 'C10' in the document (full identifier N5KG1_C10_LH) [4].
Database Links
Specialist databases
IMGT/mAb-DB 647
Other databases
GtoPdb PubChem SID 318164811
Search PubMed clinical trials burosumab
Search PubMed titles burosumab
Search PubMed titles/abstracts burosumab